ALPHEN AAN DEN RIJN, Niederlande–(BUSINESS WIRE)–Wolters Kluwer Legal & Regulatory kondigt vandaag aan dat content van Kluwer Law International wordt geïntegreerd in Libra by Wolters Kluwer, de alles-in-één juridische AI-workspace. Klanten in 11 Europese landen hebben nu rechtstreeks vanuit Libra toegang tot content van Kluwer Arbitration, Kluwer Competition Law en Kluwer IP Law. Daarmee wordt het aanbod van gezaghebbende juridische content en expertinzichten op het platform verder uitgeb
Month: September 2026
- A potent and selective PAD4 inhibitor demonstrates efficacy comparable to an anti-TNFα biologic in a mouse model of arthritis
15 September 2026 – C4X Discovery Holdings Ltd (“C4XD”), a pioneering Drug Discovery company, today announces further progress in its small molecule PAD4 inhibitor programme. C4XD’s lead compound achieved activity comparable to an anti-TNFα biologic in a mouse collagen-induced arthritis (CIA) model. This result underlines the potential of the company’s oral small molecule programme, which could offer rheumatoid arthritis patients a more convenient alternative to injectable biologic therapy.
Nick Ray, CSO of C4X Discovery, commented: “The demonstration of efficacy in a relevant disease model is a key milestone in any drug discovery project. A lead compound from our small molecule PAD4 inhibitor programme has shown activity at 10mg/kg after oral dosing with activity equivalent to etanercept, an anti TNFα biologic that has been a cornerstone of rheumatoid arthritis treatment for close to three decades. To reach that level with an oral small molecule, coupled with its encouraging selectivity profile, we are confident that a pre-clinical candidate is within reach.”
Emma Blaney, CEO of C4X Discovery, said: “C4XD has a strong track record of partnering pre-clinical programmes at various stages in the drug discovery process; we plan to continue partnering discussions for our PAD4 programme during the remainder of 2026. Additionally, we continue to advance our α4β7 programme whilst holding partnering discussions, alongside recent clinical progress under our AstraZeneca-partnered NRF2 programme1. We’d like to thank our staff and investors for their continued support to advance our programmes so that we can collaborate with the best partners to take them forward into the clinic.”
C4XD’s pipeline spans several high-value immuno-inflammatory indications. The company is currently advancing best-in-class oral α4β7 inhibitors alongside a first-in-class PAD4 programme, encompassing both innovative monotherapies and strategic combination approaches across multiple therapeutic areas.
Rheumatoid arthritis (RA) is a systemic autoimmune disease of the synovial tissue in the joints. Symptoms range from swelling and pain to bone erosion and debilitating joint destruction. Anti-Citrullinated Protein Autoantibodies (ACPAs) are found in up to 70% of RA patients, often years before clinical symptoms appear, suggestive of their role in driving disease2. PAD4 is a key enzyme in the generation of the citrullinated antigens targeted by ACPAs, and in the formation of neutrophil extracellular traps (NETs), which contribute to a range of immune-mediated conditions including lupus, renal, cardiovascular and respiratory diseases. A small molecule PAD4 inhibitor offers pipeline-in-a-product potential across multiple high-value autoimmune and inflammatory indications with considerable unmet need. Alongside our α4β7 programme, PAD4 gives us another complementary mechanism across immuno-inflammatory disease.
- https://c4xdiscovery.com/c4x-discovery-to-receive-milestone-payment-for-nrf2-exclusive-worldwide-license-agreement/
- van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7(5):R949–58. doi: 10.1186/ar1767.
– Ends –
Contacts
| C4X Discovery Holdings | |
| Emma Blaney, Nick Ray, Flora Shimi | +44 (0)161 235 5085 |
| C4X Discovery Media – ICR Healthcare | |
| Mary-Jane Elliott, Angela Gray, Tom Daniel | +44 (0)203 709 5700 |
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world leading next-generation oral medicines. Our enhanced molecular design capabilities deliver a highly differentiated approach to drug discovery, demonstrated by three high-value programmes successfully out-licensed to date. C4XD’s pipeline of small-molecule programmes spans several high-value immuno-inflammatory indications. The company is currently advancing a best-in-class oral α4β7 programme and a first-in-class PAD4 programme. Our strategy is to move these programmes to candidate stage where we look to out-license or collaborate with the best partners to execute clinical development and commercialisation.
For more information visit us at www.c4xdiscovery.com
LONDON, Sept. 15, 2026 (GLOBE NEWSWIRE) — The global power sector is becoming increasingly central to economic growth as artificial intelligence, digital infrastructure, advanced manufacturing and the electrification of transport, buildings and industry increase demand for stable, reliable and available power. At the same time, geopolitical and policy uncertainty, ageing assets, supply-chain bottlenecks and uneven grid infrastructure are shaping the direction and pace of change, according to the latest Power Market Review published today by Willis, a WTW business (NASDAQ: WTW).
The power insurance market remains highly competitive, as the wider insurance market experiences continued softening. Property capacity is abundant, rates continue to fall and insurers are actively seeking growth. Well-managed power companies with strong loss records, credible valuations and robust engineering information are using the soft market to rebalance their risk strategy, but catastrophe-exposed assets, vulnerable supply chains, emerging technologies and risks with weak maintenance or operational data will continue to attract closer underwriting scrutiny in the year ahead.
Although falling rates may create immediate savings, organisations should be exploring opportunities to leverage today’s market to strengthen resilience and prepare for a future change in the market cycle. Power companies can capitalise on current market conditions by reassessing their program structures and challenging existing pricing and design.
Key findings from the report include:
- Power investment is not moving in one direction. Technology companies, infrastructure investors and some private equity funds are all looking for ways to improve efficiency, reliability and the carbon profile of power systems. Investment activity is increasingly targeting technologies capable of delivering step-change improvements in power generation and system performance.
- Nuclear investment is accelerating, but financing remains constrained by concerns over delays, cost overruns and execution risk. The insurance market has an opportunity to help bridge this bankability gap through innovative risk transfer solutions, performance guarantees and portfolio-based approaches that give lenders greater confidence and unlock capital for project delivery.
- Capacity for coal is still available for well-managed risks, although insurer scrutiny is expected to intensify over time. The best insurance outcomes will depend on how clearly insurance buyers evidence risk quality, asset stewardship, transitional plans, maintenance regimes, business interruption exposures and portfolio-level resilience.
- For international liability, conditions continue to be increasingly favourable for buyers, due to increasing capacity, heightened competition and greater pricing flexibility. However, certain exposures remain subject to greater underwriting scrutiny such as wildfire and bushfire exposure, grid resilience, failure to supply and coal-related risks.
- Demand for power continues to increase exponentially, pulling capital into the sector but it remains bound by macro M&A transaction trends. Private equity companies are facing constrained exits, longer holding periods and challenging fundraising conditions. Deal ambition remains, but the route to execution is becoming more selective, more strategic and more dependent on risk quality.
Rob Hale, global head of power and renewable energy, Willis Natural Resources, said: “Current market conditions offer more than the chance to reduce costs, they create an opportunity to challenge insurance program architecture and reinvest into resilience before conditions become more challenging. In an interconnected energy system, insurance is not simply a mechanism for transferring loss. Used strategically, it can support investment, protect capital, strengthen resilience and give power companies greater confidence to grow.
“The companies that benefit the most from this cycle will be those that use today’s conditions to build stronger, better-evidenced and more future-ready risk financing strategies. Innovation and collaboration across all stakeholders in the value chain, including risk intermediaries, will play an increasingly critical role in de-risking investors’ capital and unblocking continued growth.”
The complete report can be downloaded here.
About WTW
At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk, and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce, and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you.
Media Contacts
Jo Barrett
Jo.Barrett@wtwco.com
Lauren David
Lauren.David@wtwco.com
VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — Eldorado Gold Corporation (TSX: ELD, NYSE: EGO) (“Eldorado” or the “Company”) today announced it will host a site tour of its Kassandra Mines assets, Skouries and Olympias, from September 15 to 18th, 2026 for analysts and institutional investors. The tour will showcase Eldorado’s exploration activities across Greece.
The site tour presentation is available for download on the Company’s website via the following link: https://www.eldoradogold.com/investors/events-webcasts/greek-asset-site-tour
About Eldorado Gold
Eldorado is a gold, copper and base metals producer with mining, development and exploration operations in Canada, Türkiye, and Greece. The Company has a highly skilled and dedicated workforce, safe and responsible operations, a portfolio of high-quality assets, and long-term partnerships with local communities. Eldorado’s common shares trade on the Toronto Stock Exchange (TSX: ELD) and the New York Stock Exchange (NYSE: EGO).
Contact
Investor Relations
Lynette Gould, VP, Investor Relations, Communications & External Affairs
647 271 2827 or 1 888 353 8166
lynette.gould@eldoradogold.com
Media
Chad Pederson, Director, Communications and Public Affairs
236 885 6251 or 1 888 353 8166
chad.pederson@eldoradogold.com
SINGAPORE–(BUSINESS WIRE)–Thredd, la piattaforma di elaborazione di carte basata sull’AI, oggi ha annunciato che iPayLinks, una piattaforma di pagamento specializzata in soluzioni internazionali e liquidazione di capitali leader nel settore, ha scelto Thredd per alimentare il suo nuovo programma Mastercard di carte di debito commerciali virtuali. Il programma, il cui lancio è previsto per la fine del terzo trimestre, estende la proposta internazionale di iPayLinks relativa all’emissione di ca
VANCOUVER, British Columbia–(BUSINESS WIRE)– #Agritech–Rx Networks, a provider of GNSS assistance and correction services, today announced the availability of TruePoint.CM, Rx Networks’ Network RTK offering within its broader TruePoint portfolio, in North America and Latin America. TruePoint.CM is designed for professional and commercial users who require reliable centimeter-level positioning, making it an ideal solution for applications such as surveying, precision agriculture, mining, construction, ma
AMSTERDAM–(BUSINESS WIRE)–Traefik Labs today introduced the Sovereign Trust Plane (STP), a set of capabilities in Traefik Hub that brings verifiable evidence to AI agent governance, with general availability planned by September 30, 2026. STP connects delegated access, policy enforcement and protected records of what the gateway allowed and refused across model, tool and API traffic. As agents begin issuing refunds, accessing customer data and changing business records, accountability reaches
新加坡–(BUSINESS WIRE)–(美国商业资讯)– 以AI为核心的发卡机构处理平台Thredd今日宣布，领先的跨境支付与资金结算平台iPayLinks已选择Thredd为其全新的Mastercard虚拟商业借记卡项目提供技术支持。 该项目预计将于第三季度末前推出，标志着iPayLinks将其跨境业务版图拓展至发卡领域，为其客户提供一种跨市场转移和使用资金的快速、安全途径。通过此次合作，iPayLinks将作为自发卡机构，完全掌控其卡项目及消费控制，而Thredd则通过专为快速上市与规模化扩展而打造的单一云原生平台提供底层处理服务，涵盖BIN码与项目设置、3D安全验证以及欺诈与交易监控。 Thredd亚太区负责人Damien Gough表示：“iPayLinks打造了一个综合性平台，帮助企业简化跨境资金的流转与管理。虚拟商业借记卡的推出是该业务主张的自然延伸，为iPayLinks及其客户提供了另一种安全高效的支付选择。我们很高兴能以运营现代商业卡项目所需的可扩展处理基础设施、欺诈监控和支付专业知识，来支持该项目的上线。” iPayLinks创始人兼首席执行官Gunther
SINGAPORE–(BUSINESS WIRE)–Thredd, the AI-first issuer processing platform, today announced that iPayLinks, a leading cross-border payment and capital settlement platform, has selected Thredd to power its new Mastercard virtual commercial debit card programme. The programme, expected to launch by the end of Q3, extends iPayLinks’ cross-border proposition into card issuing, giving its customers a fast, secure way to move and spend funds across markets. Through the partnership, iPayLinks acts as
PARIS–(BUSINESS WIRE)–For three and a half centuries, the Opéra national de Paris has been the heartbeat of the performing arts world. To ensure this storied past remains accessible to future audiences, the Opéra is partnering with Iron Mountain (NYSE: IRM) to preserve, digitize, and enhance access to the institution’s visual collections. Drawing on Iron Mountain’s 75-year history of innovation, specialized expertise, and the Insight® DXP suite of solutions, the Opéra will make select heritag